Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

Mahoney, Emilia; Byrd, John C.; Johnson, Amy J.
March 2013
Autophagy;Mar2013, Vol. 9 Issue 3, p434
Academic Journal
No abstract available.


Related Articles

  • Effect of P-glycoprotein on flavopiridol sensitivity. Boerner, S A; Tourne, M E; Kaufmann, S H; Bible, K C // British Journal of Cancer;5/15/2001, Vol. 84 Issue 10, p1391 

    Flavopiridol is the first potent inhibitor of cyclin-dependent kinases (CDKs) to enter clinical trials. Little is known about mechanisms of resistance to this agent. In order to determine whether P-glycoprotein (Pgp) might play a role in flavopiridol resistance, we examined flavopiridol...

  • Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs. Kryatof, Vladimír; Uldrijan, Stjepan // Current Drug Targets;Mar2010, Vol. 11 Issue 3, p291 

    Poor therapeutic outcomes and serious side effects, together with acquired resistance to multiple drugs, are common problems of current cancer therapies. Therefore, there is an urgent need for new cancer-targeted drugs, which has led (inter alia) to the development of molecules that can...

  • Targeting ER stress--induced autophagy overcomes BRAF inhibitor resistance in melanoma. Xiao-Hong Ma; Sheng-Fu Piao; Dey, Souvik; Mcafee, Quentin; Karakousis, Giorgos; Villanueva, Jessie; Hart, Lori S.; Levi, Samuel; Hu, Janice; Gao Zhang; Lazova, Rossitza; Klump, Vincent; Pawelek, John M.; Xiaowei Xu; Wei Xu; Schuchter, Lynn M.; Davies, Michael A.; Herlyn, Meenhard; Winkler, Jeffrey; Koumenis, Constantinos // Journal of Clinical Investigation;Mar2014, Vol. 124 Issue 3, p1406 

    Melanomas that result from mutations in the gene encoding BRAF often become resistant to BRAF inhibition (BRAFi), with multiple mechanisms contributing to resistance. While therapy-induced autophagy promotes resistance to a number of therapies, especially those that target PI3K/mTOR signaling,...

  • Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro. Cihalova, Daniela; Staud, Frantisek; Ceckova, Martina // Cancer Chemotherapy & Pharmacology;Jul2015, Vol. 76 Issue 1, p105 

    Purpose: ATP-binding cassette (ABC) transporters play an important role in multidrug resistance (MDR) toward anticancer drugs. Here, we evaluated interactions of cyclin-dependent kinase inhibitors (CDKi) AT-7519, flavopiridol and SNS-032 with the following ABC transporters in vitro:...

  • Dangerous liaisons: flirtations between oncogenic BRAF and GRP78 in drug-resistant melanomas. Shenolikar, Shirish // Journal of Clinical Investigation;Mar2014, Vol. 124 Issue 3, p973 

    BRAF mutations in aggressive melanomas result in kinase activation. BRAFV600E inhibitors reduce BRAF tumors, but rapid resistance follows. In this issue of the JCI, Ma and colleagues report that vemurafenib activates ERV600E stress and autophagy in BRAF melanoma cells, through sequestration of...

  • Autophagy in breast cancer and its implications for therapy. Jain, Kirti; Paranandi, Krishna S.; Sridharan, Savitha; Basu, Alakananda // American Journal of Cancer Research; 

    Autophagy is an evolutionarily conserved process of cellular self-digestion that serves as a mechanism to clear damaged organelles and recycle nutrients. Since autophagy can promote cell survival as well as cell death, it has been linked to different human pathologies, including cancer. Although...

  • JNK and Macroautophagy Activation by Bortezomib Has a Pro-Survival Effect in Primary Effusion Lymphoma Cells. Granato, Marisa; Santarelli, Roberta; Lotti, Lavinia V.; Di Renzo, Livia; Gonnella, Roberta; Garufi, Alessia; Trivedi, Pankaj; Frati, Luigi; D’Orazi, Gabriella; Faggioni, Alberto; Cirone, Mara // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Understanding the mechanisms of autophagy induction and its role during chemotherapeutic treatments is of fundamental importance in order to manipulate it to improve the outcome of chemotherapy. In particular whether the bortezomib-induced autophagy plays a pro-survival or pro-death role is...

  • The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells. Hayashi, Takuro; Adachi, Kazuhide; Ohba, Shigeo; Hirose, Yuichi // Journal of Neuro-Oncology;Nov2013, Vol. 115 Issue 2, p169 

    The recent progress in chemotherapy for malignant gliomas is attributable to the introduction of the DNA-methylating agent temozolomide (TMZ); however, drug resistance remains a major issue. Previous studies have shown that TMZ induces prolonged arrest of human glioma cells in the G2/M phase of...

  • Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia. El-Khoury, V; Pierson, S; Szwarcbart, E; Brons, N H C; Roland, O; Cherrier-De Wilde, S; Plawny, L; Van Dyck, E; Berchem, G // Leukemia (08876924);Aug2014, Vol. 28 Issue 8, p1636 

    Evading apoptosis is a hallmark of B-cell chronic lymphocytic leukemia (CLL) cells and an obstacle to current chemotherapeutic approaches. Inhibiting histone deacetylase (HDAC) has emerged as a promising strategy to induce cell death in malignant cells. We have previously reported that the HDAC...

  • Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-?B-dependent process. Dai, Yun; Rahmani, Mohamed; Grant, Steven // Oncogene;10/16/2003, Vol. 22 Issue 46, p7108 

    Interactions between proteasome and cyclin-dependent kinase inhibitors have been examined in human leukemia cells in relation to induction of apoptosis. Simultaneous exposure (24?h) of U937 myelomonocytic leukemia cells to 100?nM flavopiridol and 300?nM MG-132 resulted in a marked increase in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics